Clinical trial
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
NCT03217422 · Novartis Pharmaceuticals, Industry · Active, not recruiting
Key facts
| NCT number | NCT03217422 |
|---|---|
| Title | ADCC Mediated B-Cell dEpletion and BAFF-R Blockade |
| Official title | A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis |
| Acronym | AMBER |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Autoimmune Hepatitis |
| Intervention type | Biological, Other |
| Interventions | VAY736, Placebo |
| Enrollment | 68 |
| Start date | Feb 15, 2018 |
| Primary completion | Dec 28, 2023 |
| Completion | Dec 25, 2025 |
| First posted | Jul 14, 2017 |
| Last update posted | Dec 22, 2025 |
| Countries | Argentina, Belgium, Canada, Czechia, Germany, Japan, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: